LMR Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $86M | Buy |
93,539
+82,507
| +748% | +$83.6M | 0.19% | 53 |
|
|
2025
Q4 | $11.9M | Buy |
11,032
+9,747
| +759% | +$9.32M | 0.02% | 322 |
|
|
2025
Q3 | $980K | Sell |
1,285
-5,538
| -81% | -$4.12M | ﹤0.01% | 941 |
|
|
2025
Q2 | $5.32M | Buy |
6,823
+319
| +5% | +$248K | 0.04% | 424 |
|
|
2025
Q1 | $5.37M | Buy |
6,504
+3,271
| +101% | +$2.72M | 0.05% | 383 |
|
|
2024
Q4 | $2.5M | Sell |
3,233
-1,035
| -24% | -$857K | 0.02% | 540 |
|
|
2024
Q3 | $3.78M | Buy |
4,268
+3,769
| +755% | +$3.39M | 0.03% | 434 |
|
|
2024
Q2 | $452K | Sell |
499
-4,932
| -91% | -$3.95M | ﹤0.01% | 786 |
|
|
2024
Q1 | $4.23M | Buy |
+5,431
| New | +$3.87M | 0.04% | 375 |
|
|
2023
Q2 | – | Sell |
-29,261
| Closed | -$12.3M | – | 1012 |
|
|
2023
Q1 | $10M | Sell |
29,261
-19,783
| -40% | -$6.67M | 0.16% | 158 |
|
|
2022
Q4 | $17.9M | Buy |
+49,044
| New | +$17.4M | 0.31% | 83 |
|
|
2021
Q4 | – | Sell |
-23,789
| Closed | -$5.5M | – | 1222 |
|
|
2021
Q3 | $5.5M | Buy |
23,789
+22,442
| +1,666% | +$5.54M | 0.06% | 233 |
|
|
2021
Q2 | $309K | Sell |
1,347
-312
| -19% | -$62.7K | ﹤0.01% | 740 |
|
|
2021
Q1 | $310K | Buy |
+1,659
| New | +$325K | 0.01% | 724 |
|
|
2020
Q3 | – | Sell |
-30,867
| Closed | -$5.07M | – | 553 |
|
|
2020
Q2 | $5.07M | Buy |
+30,867
| New | +$4.74M | 0.13% | 105 |
|
|
2019
Q4 | – | Sell |
-11,381
| Closed | -$1.27M | – | 487 |
|
|
2019
Q3 | $1.27M | Sell |
11,381
-20,901
| -65% | -$2.33M | 0.06% | 143 |
|
|
2019
Q2 | $3.58M | Buy |
+32,282
| New | +$3.8M | 0.13% | 80 |
|
|
2019
Q1 | – | Sell |
-26,631
| Closed | -$3.08M | – | 425 |
|
|
2018
Q4 | $3.08M | Buy |
+26,631
| New | +$2.97M | 0.15% | 83 |
|
|
2017
Q4 | – | Sell |
-4,677
| Closed | -$400K | – | 371 |
|
|
2017
Q3 | $400K | Sell |
4,677
-15,637
| -77% | -$1.28M | 0.04% | 209 |
|
|
2017
Q2 | $1.67M | Buy |
+20,314
| New | +$1.66M | 0.1% | 200 |
|
|
2017
Q1 | – | Sell |
-4,181
| Closed | -$307K | – | 426 |
|
|
2016
Q4 | $307K | Buy |
+4,181
| New | +$311K | 0.05% | 285 |
|
|
2016
Q1 | – | Sell |
-17,238
| Closed | -$1.45M | – | 398 |
|
|
2015
Q4 | $1.45M | Buy |
+17,238
| New | +$1.43M | 0.47% | 38 |
|
|
2015
Q3 | – | Sell |
-9,175
| Closed | -$766K | – | 417 |
|
|
2015
Q2 | $766K | Buy |
+9,175
| New | +$699K | 0.09% | 258 |
|
Other funds holding LLY
VCM
VPM
LMR Partners's LLY Position: Q1 2026 in Review
LMR Partners increased its Eli Lilly (LLY) stake by 748% in Q1 2026, buying an estimated $83.6M and bringing the position to 93,539 shares worth $86M. The position accounts for 0.19% of the portfolio, ranked #53.
LMR Partners first reported a position in LLY in Q2 2015 and has held it in 23 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- LMR Partners held 93,539 shares of Eli Lilly worth $86M as of Q1 2026.
- LMR Partners bought 82,507 Eli Lilly shares in Q1 2026, an estimated $83.6M.
- Eli Lilly made up 0.19% of LMR Partners's portfolio in Q1 2026, its #53 holding.
- LMR Partners first reported a position in Eli Lilly in Q2 2015 and has held it in 23 quarters since.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.